LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor

Table 1

LSD1 inhibitors in clinical trials.

Inhibitors	Malignancy	Study phase	Study description	Trial number
GSK2879552	Relapsed/refractory SCLC	Phase I	Single-agent	NCT02034123
GSK2879552	Relapsed/refractory AML	Phase I	Double-agent	NCT02177812
CC-90011	Relapsed/refractory solid tumors and non-Hodgkin’s lymphomas	Phase I	Single-agent	NCT02875223
IMG-7289	Acute myeloid leukemia and myelodysplastic syndrome	Phase I/IIa	Single-agent/double-agent	NCT03136185
IMG-7289	Essential thrombocythemia	Phase IIb	Single-agent	NCT04081220
IMG-7289	Myelofibrosis	Phase IIb	Single-agent	NCT03136185
TCP	Refractory/relapsed AML	Phase I/II	Double-agent	NCT02261779
TCP	Non-APL AML/MDS	Phase I/II	Triple-agent	NCT02717884
ORY-1001	Elderly AML	Phase II	Double-agent	ISIN code: ES0167733015, ORY
ORY-1001	SCLC	Phase II	Double-agent	N/A
ORY-1001	Refractory/relapsed acute leukemia patients	Phase I/IIa	Single-agent	EudraCT no.: 2018-000482-36